By Dr. Charles Kamen, MD — Board-Certified Neurologist, LiveWell21, Las Vegas, NV
Albert Einstein College of Medicine (MD, 2011) | Yale-New Haven Hospital Internship (2011–2012) | Loma Linda University Neurology Residency (2015–2018) | ABPN Board Certified
If you follow longevity science at all, you've probably encountered the term "zombie cells." It's a colorful label for a real biological phenomenon — one that researchers now believe plays a meaningful role in how we age and how age-related disease develops. The scientific term is cellular senescence, and the drugs and compounds designed to eliminate these cells are called senolytics.
This isn't fringe science. It's a field that has attracted research dollars from the National Institutes of Health, produced work from institutions like the Mayo Clinic, and spawned clinical trials now underway for conditions ranging from osteoarthritis to Alzheimer's disease. At LiveWell21 in Las Vegas, senolytic protocols are part of how I approach the biology of aging — not as a shortcut, but as a targeted intervention grounded in the mechanism of what actually happens to cells over time.
Let me explain what the science actually shows.
Every cell in your body has a finite lifespan. When a cell is damaged — by radiation, oxidative stress, DNA replication errors, or other stressors — it faces a choice. It can repair itself. It can undergo apoptosis (programmed cell death, an orderly self-elimination process). Or it can enter a state called senescence.
Senescent cells do something unusual: they stop dividing but refuse to die. They linger in the tissue. And while they're there, they secrete a complex mixture of inflammatory cytokines, chemokines, proteases, and other signaling molecules collectively called the Senescence-Associated Secretory Phenotype, or SASP.
The SASP is the problem. This inflammatory secretome — the "zombie signal," if you will — disrupts the function of neighboring healthy cells, promotes chronic low-grade inflammation, and has been implicated in multiple hallmarks of aging:
Cellular senescence isn't entirely bad. It plays a protective role in wound healing and cancer suppression — senescent cells help prevent damaged cells from dividing uncontrollably. The problem arises when the immune system's normal process of clearing senescent cells (called immune surveillance) becomes less efficient with age, and these cells begin to accumulate faster than they're cleared.
The modern scientific story of senolytics begins largely with Dr. James Kirkland and colleagues at the Mayo Clinic. A landmark 2015 study published in Aging Cell demonstrated that clearing senescent cells in mice — using a combination of dasatinib and quercetin — extended healthspan and delayed the onset of age-related disorders.1 The mice lived longer, but more importantly, they lived better: more physically capable, with less frailty and better metabolic health.
Subsequent studies from the same group found that senescent cell transplants from old mice into young, healthy mice caused the recipients to develop frailty and age-related markers faster than controls — providing causal evidence that senescent cell accumulation drives aspects of aging, not just correlates with it.2
In humans, early clinical trials are now reporting results. A 2019 pilot study from the Mayo Clinic tested dasatinib plus quercetin in patients with idiopathic pulmonary fibrosis (a devastating lung disease with strong senescence involvement). Despite the small sample size, participants showed improvements in physical function — a striking result for a disease with no previously effective treatment.3
Ongoing trials are investigating senolytic agents for:
As of this writing, senolytics remain investigational for most of these indications. The human trial data is promising but early, and we don't yet have the long-term safety and efficacy data that would support widespread clinical recommendation. I think it's important to be honest about that while also recognizing that the mechanistic rationale is sound and the early signals are compelling.
Multiple compounds have demonstrated senolytic activity — the ability to selectively eliminate senescent cells while largely sparing normal cells. The most studied include:
Originally developed as a cancer drug (an Abl/Src kinase inhibitor used in leukemia), dasatinib was identified as senolytic through a drug screening study at Mayo. It works by inhibiting survival pathways that senescent cells exploit to resist apoptosis. It's typically used in intermittent, pulsed dosing protocols — not daily — in the senolytic context.
A naturally occurring flavonoid found in foods like onions, apples, and capers, quercetin has demonstrated senolytic activity in combination with dasatinib. It appears to work through a similar mechanism — blocking survival signals in senescent cells — and has a favorable safety profile. Quercetin is available as a supplement, though bioavailability is variable; fisetin (a related flavonoid) has also shown senolytic activity in preclinical models.
Found naturally in strawberries, apples, and persimmons, fisetin has shown particularly strong senolytic activity in mouse models and favorable preliminary data in human studies. A clinical trial at Mayo evaluated fisetin in older adults and found it reduced senescent cell markers in blood.4 It's being studied in several ongoing trials.
Senescent cells survive in part by upregulating anti-apoptotic proteins like BCL-2. Drugs that block these proteins — navitoclax and related compounds — can restore the cell's ability to undergo programmed death. These are more potent but also carry more side effect risk, limiting their current application outside of cancer treatment.
NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) aren't senolytics in the strict sense — they don't directly clear senescent cells — but they support NAD+ levels, which decline with age and affect DNA repair, mitochondrial function, and the regulation of senescence-related pathways. They're often used as supporting agents in broader longevity protocols.
Senolytic therapy is not a supplement to add to your morning routine. It's a targeted biological intervention that requires clinical oversight, understanding of your individual health context, and realistic expectations about what current evidence supports.
At LiveWell21, I consider senolytic protocols for patients who:
Senolytic protocols are typically done on an intermittent basis — a short course several times per year — rather than daily. The specific protocol, agents used, and frequency depend on individual factors.
Importantly: this is not appropriate for everyone. Patients with active cancer, significant organ dysfunction, or who are on certain medications require careful evaluation before any senolytic protocol.
I want to be straightforward with patients about what we know and don't know. The human data on senolytics, while promising, is earlier-stage than, say, the evidence base for hormone therapy or peptide protocols. We don't yet have large randomized controlled trials in healthy aging adults showing that regular senolytic use extends healthspan in humans the way the mouse data suggests.
What we have is:
Some patients report subjective improvements — better energy, reduced joint discomfort, clearer cognition — following senolytic protocols. Others notice little. As with most biological interventions, individual response varies. We follow biomarkers over time to assess whether the approach is producing measurable change.
As a neurologist, I'm particularly interested in the emerging data on senolytics and the aging brain. Senescent cells have been identified in the brains of individuals with Alzheimer's disease, and preclinical work suggests that clearing them may reduce neuroinflammation and tau pathology. This is an active frontier in neurological longevity medicine, and one I follow closely.
At LiveWell21, senolytic protocols are integrated into a broader longevity framework that includes hormonal optimization, peptide therapy, metabolic monitoring, and lifestyle medicine. No single intervention exists in isolation. Clearing senescent cells while operating on poor sleep and chronic stress is like cleaning the filter while continuing to pollute the source.
If you're in Las Vegas and interested in understanding whether senolytics have a place in your health strategy, I'd invite you to schedule a consultation. We'll review your history, assess your biomarkers, and discuss where senolytic therapy fits — honestly and realistically — in your personal longevity plan.
Book a Longevity Consultation at LiveWell21
Explore related services:
Hormone Optimization | Peptide Therapy | Longevity Medicine
This content is for educational purposes and does not constitute medical advice. Senolytic agents are not FDA-approved for aging indications and should only be considered under physician supervision.